It’s fair to say that BioTech has probably never been as much in the public eye as it has been over the past two years.
And while everyone has now heard of household names, such as Pfizer, AstraZeneca, Moderna and others, there are many other BioTech startups doing amazing work and research, that may all be just on the cusp of the world’s next major bio development.
To give just a small taste of what some of these incredible companies are doing, here are some of the top 25 BioTech startups currently making a name for themselves.
Arctoris
Arctoris is a tech-enabled platform company in biotechnology, combining robotics and data science to accelerate drug discovery. Arctoris’ unique drug discovery platform uses advanced robotics, data science and an experienced team of BioTech and pharma veterans. Their team is pursuing several drug discovery programs in oncology and neuro.
2016 – Oxford, UK
Martin-Immanuel Bittner, Thomas Fleming
Total funding: $10m
Autolus
Autolus is a London based bio-technology startup specialising in T-cell programming. Autolus’ programme of development in T-cell therapies is set to be a breakthrough approach in targeting haematological cancers and solid tumours. Autolus also manufactures new technology.
Bit.bio
Bit.bio specialises in coding and biology that determine the identity of every human cell. At present, Bit.bio is developing a scalable technology platform capable of producing consistent batches of every human cell. If successful, this will enable research and drug discovery to efficiently work with cells that are affected by human disease. This will also provide the basis for a new generation of cell and tissue therapies.
2016 – Cambridge, UK
Florian Schuster, Mark Kotter
Total funding: $145m
Web: https://bit.bio/
Carbios
Carbios is a BioTech company focusing on chemical engineering. Specifically, Carbios focuses on discovering and developing enzymatic bioprocesses applied to plastic and textile polymers. Carbios creates a new generation of fully biodegradable plastics with a controlled lifespan to limit plastic waste.
2011 – Saint-beauzire, Auvergne, France
Jean-Claude Lumaret
Total funding: €17.8m
Clade Therapeutics
Clade Therapeutics is a biotechnology company that discovers and delivers medicines to improve the lives of patients. The startup focuses on next-general cell therapies.
2020 – Cambridge, Massachusetts, United States
Chad Cowan, Jim Glasheen, Leandro Vetcher
Total funding: $87m
Web: https://cladetx.com/
Compass Pathways
Compass Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Compass Pathways is developing psychedelic treatments against clinical depression based on psilocybin, the main ingredient found in magic mushrooms which are effective in treating depression.
2016 – Altrincham, Cheshire, UK
Ekaterina Malievskaia, George Goldsmith, Lars Christian Wilde
Total funding: $116.2m
DNA Script
DNA Script is a disruptive BioTech company, specialising in DNA synthesis. The team at DNA Script are currently harnessing biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world’s first benchtop DNA printer, SYNTAX.
2016 – Le Kremlin-bicêtre, Ile-de-France, France
Sylvain Gariel, Thomas Ybert, Xavier Godron
Total funding: $479.8m
EnteroBiotix
EnteroBiotix is a BioTech company that is developing ground-breaking medicinal products intended to restore health and prevent bacterial infections. EnteroBiotix is developing and advancing novel microbiome modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in the human gut.
2017 – Edinburgh, Scotland, UK
James McIlroy
Total funding: $18m
eTheRNA
eTheRNA develops immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA immunotherapies aims to help patients to overcome certain cancers and infectious diseases through their novel pathways to immunotherapy; targeting the fundamental role of dendritic cells in the immune system.
ExoTherapeutics
ExoTherapeutics is a BioTech startup specialising in small molecule drug discovery and development. ExoTherapeutics team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases.
2018 – Cambridge, Massachusetts, United States
David R. Liu
Total funding: $103m
Freeline
Freeline Therapeutics is a biotechnology company whose focus is the development of liver-directed gene therapies for a range of diseases. Their mission is to transform the lives of patients suffering from debilitating hereditary diseases. Freeline has clinical programs in Hemophilia B and Fabry disease, and additional preclinical programs in Gaucher disease and Hemophilia A.
2014 – Stevenage, Hertfordshire, UK
Amit Nathwani, Markus Hörer
Total funding: $276m
GammaDelta Therapeutics
GammaDelta Therapeutics is a BioTech startup company developing the potential of gamma delta (γδ) cells to improve immunotherapy treatment of cancer and other serious diseases. GammaDelta plans to use unique properties of tissue-resident γδ T cells to leverage effective immunotherapy.
Gedea Biotech
Gedea Biotech develops an antibiotic-free, safe and effective treatment of vaginal fungal infections. Vaginal yeast infections are a common infection that affects the majority of women at least once in their life. Gedea Biotech’s substance, GA101, is a natural substance that treats yeast infections by lowering the pH as well as providing physical barrier protection.
2015 – Lund, Skane Lan, Sweden
Helena Strevens, Olov Sterner, Sophie Manner, Ulf Ellervik
Total funding: $1.4m
Kuur Therapeutics
Kuur Therapeutics is a BioTech startup that is dedicated to transforming the lives of cancer patients. Kuur is developing off-the-shelf engineered CAR-NKT cell therapies. Their radical approach combines the highly differentiated, natural biology of a specific subset of cytotoxic T cells, called natural killer T cells (NKT cells) and innovative CAR construct engineering.
Macomics
Macomics is a BioTech startup specialising in immuno-oncology. Macomics focuses on the development of novel, first-in-class immunotherapies designed to modulate macrophages, to increase the body’s immune defence against tumours.
2020 – Edinburgh, UK
Coral Ries, Jeffrey Pollard, Luca Cassetta, Stephen Myatt
Total funding: $7.4m
Oryzon Genomics
Oryzon Genomics is a clinical‐stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases. The European BioTech is creating epigenetic drugs for the treatment of neurological diseases and cancer.
2000 – Madrid, Spain
Carlos Buesa, Tamara Maes
Total funding: $139.9m
Phytoform Labs
Phytoform Labs is a biotechnology company whose specialism is resilient and sustainable crops. The biotechnology company’s goal is to help breeders to cut down plant breeding times from a span of decades to years thanks to novel gene-editing technologies. Predictably evolving plants will maximise yields for breeders and improve the economics of breeding for customers.
2017 – Salisbury, UK
Nicolas Kral, William Pelton
Total funding: $5.8m
ReViral
ReViral is a biotechnology startup specialising in the development of antiviral therapies. ReViral hopes to expand the antiviral market with its development of novel first-in-class compounds.
ReViral has pioneered a fusion inhibitor of RSV; a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates.
2011 – Stevenage, UK
Ken Powell, Neil Mathews, Stuart Cockerill
Total funding: $121m
Scorpion Therapeutics
Scorpion Therapeutics is a biotech company that broadens the reach and impact of precision medicine in the field of oncology. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine.
2020 – Boston, Massachusetts, United States
Gaddy Getz, Gary Glick, Keith Flaherty, Liron Bar-Peled
Total funding: $270m
Solar Foods
Solar Foods is a pioneer in the alternative food space within biotechnology. The startup develops a novel nutrient-rich protein using only air and electricity as the main resources. This is a ground-breaking approach to food production, as it is not dependent on agriculture, the weather, or the climate.
2017 – Helsinki, Finland
Juha-Pekka Pitkänen, Pasi Vainikka
Total funding: $42m
Transine Therapeutics
Transine Therapeutics is a developer of a biotech platform enhancing therapeutics for the treatment of disease. The startup’s pioneering technology is expected to offer a unique mechanism for currently hard-to-treat diseases.
2018 – Cambridge, UK
Piero Carninci, Stefano Gustincich
Total funding: $12.9m
TreeFrog Therapeutics
TreeFrog Therapeutics is a biotech startup, specialising in stem cell production. This will enable millions of patients to access the medical revolution of cell therapies. The company aims to secure cell production and quality, fasten clinical development and facilitate market access.
2018 – Bordeaux, Aquitaine, France
Erwan Bezard, Jean-Luc Treillou, Kevin Alessandri, Laurent Cognet, Maxime Feyeux, Pierre Nassoy
Total funding: $86.9m
Valo Therapeutics
Valo Therapeutics is a biotech company, specialising in immuno-oncology therapy. Valo Therapeutics is developing tumour antigen-coated oncolytic viruses as therapeutic vaccines.
2018 – Helsinki, Finland
Vincenzo Cerullo
Total funding: $9.2m
Verve Therapeutics
Verve Therapeutics is a genetic medicines company creating a novel methodology for the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Verve’s goal is to discover and develop therapies that safely edit the genomes of adults to confer protection against coronary diseases.
2018 – Cambridge, Massachusetts, United States
Anthony Philippakis, Barry Ticho, Burt Adelman, Issi Rozen, J. Keith Joung, Kiran Musunuru, Sekar Kathiresan
Total funding: $215.5m
Virion Biotherapeutics
Virion Biotherapeutics is a startup that is developing biological antivirals targeted towards respiratory viral infections, including influenza and RSV. These novel treatment options will enable doctors to get a broad-spectrum therapy for respiratory viral infections, which could simplify and accelerate treatment by negating the need for differential diagnosis.
2017 – Zürich, Zurich, Switzerland
Vanessa King
Total funding: $21.2m
This list includes startups that are striving to change all our lives for the better.
Splento changes the life of people in startups – by creating visual content, tools and resources to aid marketing, attract new clients, highlight USPs, promote other advantages and much more…
As part of that role, here is our free webinar on video content and how it can help your insurance business – today.
For all your visual content you can record your videos yourself, or if you prefer – contact Splento for help.
We are experts in visual content – we make videos that make your business grow.
Contact Splento today:
Data source: crunchbase.com
Contact Splento if you are in need of:
